McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.
| Revenue (TTM) | $403.43B |
| Gross Profit (TTM) | $14.53B |
| EBITDA | $6.88B |
| Operating Margin | 2.21% |
| Return on Equity | 0.00% |
| Return on Assets | 4.99% |
| Revenue/Share (TTM) | $3264.00 |
| Book Value | $-18.10 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 0.26 |
| EV/Revenue | 0.258 |
| EV/EBITDA | 14.51 |
| Quarterly Earnings Growth (YoY) | 37.20% |
| Quarterly Revenue Growth (YoY) | 6.00% |
| Shares Outstanding | $117.08M |
| Float | $120.01M |
| % Insiders | 0.05% |
| % Institutions | 95.32% |
Volatility is currently expanding
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) closed at $831.46 in the latest trading session, marking a -1.18% move from the prior day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) closed at $803.37 in the latest trading session, marking a -1.1% move from the prior day.
McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article.
Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MCK and any ticker you trade — then tracks every position and per-strategy win rate.
